Rabbit anti-Human BRCA1 Polyclonal Antibody | anti-BRCA1 antibody

BRCA1 (C21) Antibody

Cat. Num. AAA440100

• Gene Names: BRCA1; IRIS; PSCP; BRCAI; BRCC1; FANCS; PNCA4; RNF53; BROVCA1; PPP1R53
• Reactivity: Human
• Applications: Western Blot, Immunoprecipitation, Immunohistochemistry
• Synonyms: BRCA1; Polyclonal Antibody; BRCA1 (C21) Antibody; anti-BRCA1 antibody

• Host: Rabbit
• Reactivity: Human
• Clonality: Polyclonal
• Specificity: Recognizes Human BRCA1
• Form/Format: 200 ug/ml rabbit polyclonal IgG in 1 ml PBS containing 0.1 % sodium azide and 0.2% gelatin.
• Concentration: 0.200 mg/ml (varies by lot)
• Sequence Length: 1863

• Applicable Applications for anti-BRCA1 antibody: Western Blot (WB), Immunoprecipitation (IP), Immunohistochemistry (IHC)
• Application Notes: Western blotting starting dilution: 1:200.
• Origin: BRCA1 (C21) is an affinity purified rabbit polyclonal antibody, raised against a peptide mapping to the carboxy terminus of human BRCA1.
• Immunogen: A synthetic peptide mapping to the carboxy terminus of human BRCA1.
• Preparation and Storage: Store this product at 4 degree C, do not freeze. The product is stable for one year from the date of shipment.

Related Product Information for anti-BRCA1 antibody

The breast cancer susceptibility gene 1 (BRCA1) gene was isolated in 1994. Mutations of the gene, a tumor suppressor, are associated with an increased risk for breast, ovarian, and prostate cancers. (1) Point mutations in critical domains and frameshift mutations that lead to early termination of protein translation are associated with a 60-80% risk of breast cancer and a 20-40% risk of ovarian cancer in some studies. (2) BRCA1 is highly polymorphic with more than 1,200 distinct documented variants. Approximately 70% of reported variants lead to absence of full-length BRCA1 protein and are suspected to predispose to cancer. (3) BRCA1 contains several functional domains that directly or indirectly interact with a variety of proteins via protein-protein interaction; these include tumor suppressors (BRCA2, p53, Rb and ATM), oncogenes (c-Myc, casein kinase II and E2F), DNA damage repair proteins (RAD50 and RAD51), cell cycle regulators (cyclins and cyclin dependent kinases), transcriptional activators and repressors (RNA polymerase II, RHA, histone deacetylase complex and CtIP), DNA damage-sensing complex and mismatch repair proteins (BRCA1- Associated Surveillance Complex; BASC) and signal transducer and activator of transcription (STAT). BRCA1 plays a significant role in maintaining genomic stability and serves as a tumor suppressor in breast cancer tumorigenesis. (4)

References

1. Bae I, Fan S, Meng Q, Rih JK, Kim HJ, Kang HJ, Xu J, Goldberg ID, Jaiswal AK, Rosen EM. BRCA1 Induces Antioxidant Gene Expression and Resistance to Oxidative Stress. Cancer Res. 2004 Nov 1;64(21):7893-7909.2. Brose MS, Volpe P, Paul K, Stopfer JE, Colligon TA, Calzone KA, Weber BL. Characterization of two novel BRCA1 germ-line mutations involving splice donor sites. Genet Test. 2004 Summer;8(2):133-8.3. Szabo CI, Worley T, Monteiro AN. Understanding Germ-Line Mutations in BRCA1. Cancer Biol Ther. 2004 Jun;3(6):515-20. 4. Jhanwar-Uniyal M. BRCA1 in cancer, cell cycle and genomic stability. Front Biosci. 2003 Sep 01;8:s1107-17.

NCBI and Uniprot Product Information

• NCBI GI #: 1698399
• NCBI GeneID: 672
• UniProt Accession #: P38398; O15129; Q1RMC1; Q3LRJ0; Q3LRJ6; Q6IN79; Q7KYU9; E9PFZ0
• Molecular Weight: 202,342 Da
• NCBI Official Full Name: BRCA1
• NCBI Official Synonym Full Names: breast cancer 1, early onset
• NCBI Official Symbol: BRCA1
• NCBI Official Synonym Symbols: IRIS; PSCP; BRCAI; BRCC1; FANCS; PNCA4; RNF53; BROVCA1; PPP1R53
• NCBI Protein Information: breast cancer type 1 susceptibility protein; BRCA1/BRCA2-containing complex, subunit 1; Fanconi anemia, complementation group S; RING finger protein 53; breast and ovarian cancer susceptibility protein 1; breast and ovarian cancer sususceptibility protein 1; protein phosphatase 1, regulatory subunit 53; truncated breast and ovarian cancer susceptibility protein 1
• UniProt Protein Name: Breast cancer type 1 susceptibility protein
• Protein Family: BRCA1-A complex
• UniProt Gene Name: BRCA1
• UniProt Synonym Gene Names: RNF53
• UniProt Entry Name: BRCA1_HUMAN

NCBI Description

This gene encodes a nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants, some of which are disease-associated mutations, have been described for this gene, but the full-length natures of only some of these variants has been described. A related pseudogene, which is also located on chromosome 17, has been identified. [provided by RefSeq, May 2009]

Uniprot Description

BRCA1: the BRCA1-BARD1 heterodimer coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Acts by mediating ubiquitin E3 ligase activity that is required for its tumor suppressor function. Plays a central role in DNA repair by facilitating cellular response to DNA repair. Required for appropriate cell cycle arrests after ionizing irradiation in both the S-phase and the G2 phase of the cell cycle. Involved in transcriptional regulation of P21 in response to DNA damage. Required for FANCD2 targeting to sites of DNA damage. May function as a transcriptional regulator. Inhibits lipid synthesis by binding to inactive phosphorylated ACC1 and preventing its dephosphorylation. Defects in BRCA1 are a cause of genetic susceptibility to breast cancer. Mutations in BRCA1 are thought to be responsible for more than 80% of inherited breast-ovarian cancer. Part of the BRCA1-associated genome surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1, ATM, BLM, PMS2 and the RAD50-MRE11-NBN protein complex. This association may be a dynamic process changing throughout the cell cycle and within subnuclear domains. Interacts (via BRCT domains) with CTIP. Associates with RNA polymerase II holoenzyme. Interacts with SMC1 and COBRA1. Interacts (via BRCT domains) with BRIP1. Interacts with FANCD2 (ubiquitinated). Interacts with BAP1. Interacts with Artemis and claspin. Interacts with H2AFX (phosphorylated on S140). Interacts with CHK1. Interacts with BRCC3. Five human isoforms are produced by alternative splicing and alternative initiation. Isoform 1 and isoform 3 are widely expressed. Isoform 1 is largely nuclear, while isoforms 3 and 5 are cytoplasmic.

Protein type: Nuclear receptor co-regulator; Ubiquitin ligase; Tumor suppressor; EC 6.3.2.-; Ubiquitin conjugating system; Transcription, coactivator/corepressor

Chromosomal Location of Human Ortholog: 17q21

Cellular Component: nucleoplasm; gamma-tubulin ring complex; condensed nuclear chromosome; protein complex; cytoplasm; BRCA1-BARD1 complex; plasma membrane; chromosome; ribonucleoprotein complex; nucleus; ubiquitin ligase complex

Molecular Function: tubulin binding; protein binding; enzyme binding; androgen receptor binding; DNA binding; zinc ion binding; RNA binding; ubiquitin protein ligase binding; transcription coactivator activity; ubiquitin-protein ligase activity; damaged DNA binding; ligase activity

Biological Process: genetic imprinting; apoptosis; positive regulation of transcription, DNA-dependent; dosage compensation, by inactivation of X chromosome; centrosome cycle; protein ubiquitination; negative regulation of histone H3-K4 methylation; positive regulation of histone H3-K4 methylation; chromosome segregation; negative regulation of histone acetylation; regulation of apoptosis; DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; double-strand break repair; DNA replication; fatty acid biosynthetic process; negative regulation of fatty acid biosynthetic process; positive regulation of histone H3-K9 methylation; negative regulation of histone H3-K9 methylation; protein autoubiquitination; chordate embryonic development; positive regulation of DNA repair; postreplication repair; DNA repair; negative regulation of centriole replication; double-strand break repair via homologous recombination; regulation of cell proliferation; regulation of transcription from RNA polymerase II promoter; positive regulation of angiogenesis; DNA damage response, signal transduction resulting in induction of apoptosis; regulation of transcription from RNA polymerase III promoter; response to estrogen stimulus; positive regulation of protein ubiquitination; androgen receptor signaling pathway; positive regulation of transcription from RNA polymerase II promoter; positive regulation of histone acetylation; response to ionizing radiation; negative regulation of transcription, DNA-dependent; G2/M transition DNA damage checkpoint; response to DNA damage stimulus

Disease: Breast-ovarian Cancer, Familial, Susceptibility To, 1; Pancreatic Cancer, Susceptibility To, 4; Breast Cancer